We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Sondrel (holdings) Plc | SND | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.28 | 7.00% | 4.28 | 16:35:01 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 4.00 | 4.00 | 4.15 | 4.28 | 4.00 |
| Industry Sector |
|---|
| SOFTWARE & COMPUTER SERVICES |
| Top Posts |
|---|
Posted at 05/5/2024 08:41 by researchguru1 JH, by way of background, I investigated both scenarios (an institutional investor exit, and an institutional investor entry) and came to the conclusion that the latter was probably the most plausible based on the past three days’ trading pattern (Buy and Sell volumes against the ‘real’ mid-price).Of course, there’s always the scenario where a ‘Sell Order’ was placed six days ago and was being worked through during the past four days? In this scenario, your conclusion would have some weight, albeit the absence of a material drop in the share price, for that number of shares, seems odd considering the tight free float. Either way, both scenarios are extremely bullish for the company: a) An institutional investor exit means that, a large stock overhang has now been removed. b) An institutional investor entry, on the other hand, means that, the free float just got tighter and the battle for the company is well and truly on. Thus, I have a strong feeling that, the share prices we are witnessing now will be a distant memory in short order. . |
Posted at 01/5/2024 08:10 by researchguru1 POSTED BY SM1 ON THE LSE BBFor those unaware, the latest ‘Significant Shareholders’ data has been published on the company’s website. The data was updated on 19 April 2024 – the day our Interim CEO and CFO unleashed their wallets. The updated data reveals the ‘forced’ (statutory liquidation requirement) departure of Joh. Berenberg, Gossler & Co. (4.66%) and Herald Investment Management (4.16%). They join Perpetual (3.95%) and CRUX Asset Management (4.51%) who exited shortly after the delisting announcement on the 28 March 2024. Otus Capital Management (4.75%) and Lansdowne Partners International (4.51%), on the other hand, emerge as the only remaining institutional investors in the company, albeit with reduced stakes. This means that, including the sold-off stakes of the existing institutional investors, a significant stock overhang of some 20,369,846 shares (23.29% of the issued share capital) was worked through between 11 April 2024 and 18 April 2024; a period that saw 22m shares change hands and a share price under sustained pressure. And the resulting uptrend in the company’s share price, from the 22 April onwards, confirms the removal of the stock overhang. Of course, most of that stock appears to have been mopped-up by private investors (‘Longs’ It goes without saying, a free float of that size means that, any sustained buying pressure is now likely to put a rocket under the shares. In the meantime, and following last Friday’s takeover of Darktrace by the Chicago-based, private equity firm Thoma Bravo, the UK has now become the ultimate fishing pond for US companies and investors looking for outstanding, GROSSLY UNDERVALUED, British tech companies: AIMHO . |
Posted at 29/4/2024 12:41 by john henry Source the only news that will move the share price is an offer for the company.SND is going private, market/Investors simply not interested. |
Posted at 22/4/2024 21:09 by researchguru1 POSTED ON THE LSE BB BY SM1I mentioned in my previous post (of 17th April) that the head honchos of C4X Discovery, Molecular Energies, and Redx Pharma (Clive Dix, Peter Levine, and Lisa Anson) had all swooped-in and picked-up their company’s stock at ‘fire-sale&rsq Well, and as if on cue, Sondrel has just ticked that box with the CEO and CFO’s bargain share purchase at 3.50-3.60p per share only 3 weeks after their ‘delisting&rsq And why isn’t this a surprise? The company’s stock, as previously stated, is incredibly undervalued across all industry benchmarks, and probably the most undervalued chip maker in Europe. But more importantly, private investors have been given the clearest indicator of the material mispricing on display through the cornerstone investor’s funding commitment at 10p per share – WHICH SET A NEW FLOOR FOR THE SHARE PRICE. And let’s not forget House Broker Cavendish’s Target Price for the company’s shares of 20p per share based on Sondrel’s UK peer group valuation. In the meantime, private investors should be aware of ROX’s unspoken modus operandi: • SILVERBRIDGE DELISTING ON THE CARDS AFTER UK FIRM POUNCES (April 2022) "The deal must be concluded by 31 August 2022 – including receiving the necessary regulatory approvals. Also, SilverBridge must have applied to the JSE by this date for the termination of the company’s listing on the bourse’s main board." • SILVERBRIDGE TO REMAIN LISTED AFTER ALL (June 2022) "Technology services company SilverBridge will remain listed on the JSE after all, after its acquirer, UK-based ROX Equity Partners, agreed to waive the delisting requirement in its offer. ROX has waived several other conditions, greasing the wheels to the conclusion of the buyout – pending mandatory regulatory approvals." “Everyone has a will to win, but very few have the will to prepare to win.” (Vince Lombardi) Make sure you are part of the few. This stock (share price) will look very different in a very short space of time. AIMHO . |
Posted at 17/4/2024 07:58 by researchguru1 POSTED ON LSE BY SM1Sorcerer, your description of Sondrel as a business with “market leading capabilities, contracted future revenues of $200m, and a strong sales pipeline in a pivotal growth industry”, is bang on the money. The company’s ultra-complex chips offer significant scale improvement when it comes to latency, privacy, security, and increased efficiency; making it one of only a tiny handful of companies out there that are able to do this, and which explains why Elon Musk’s brain implant start-up, Neuralink™, called on the company for its expertise in designing its brain chip. Now, let’s just think about that for a moment. Why has a $5 billion-capped US biotech sought assistance from an off-the-radar British nano-cap? What kind of expertise does it have that is clearly out of the reach of the thousands of US chip makers accessible to Elon Musk? And what’s the inherent value of this expertise/business? The answer to those questions is the reason why institutional investors Otus Capital Management (7.28%), Joh. Berenberg, Gossier (4.66%), Herald Investment Management (4.16%), and Lansdowne Partners (4%) are still here, and why an estimated 17% of the stock is currently held by private investors. But a £3.3m market cap (3.85p per share) simply does not cut it! Which is why I remain fully invested because, as you rightly put it, there are several possible outcomes here; some pretty spectacular, but none that is likely to value the business anywhere close to where it is today. And a quick glance at the recent ‘delisting stocks’, and how they have performed since their delisting announcement, paints an interesting picture of a fast-evolving, private investor perception of these stocks. Put simply, nearly all the stocks have staged a strong recovery meaning that, private investors are prioritising value over exploitative ‘engineered fear’ by some greedy actors within those businesses. Take C4X Discovery, Molecular Energies, and Redx Pharma for example; a week after their delisting announcements, the head honchos (Clive Dix, Peter Levine, and Lisa Anson) swooped-in and picked-up stock at ‘fire-sale&rsq So private investors are not going to fall for the copper-plated nonsense being spouted by some of these greedy actors who want to steal the business under their noses. And Sondrel, which is incredibly undervalued across all industry benchmarks, and probably the most undervalued chip maker in Europe, is going to trump all these companies and change the narrative. Watch this space. And yes, I agree – this is what makes the current situation with SND so interesting. AIMHO . |
Posted at 11/3/2024 07:36 by cyberbub Raising equity is never welcome, but if all/most of it goes to a single strategic shareholder then they won't be selling for a quick 10% profit like many so-called 'investors'. Rox must have done substantial due diligence about Sondrel's business model and financial prospects, so that gives some hope, to me anyway. I did decide to buy in on Friday for that reason... GLA NAI etc |
Posted at 08/3/2024 18:11 by cyberbub I suppose that investors may now be working on the assumption that there are 150M-odd shares in issue, and valuing Sondrel on that basis. I note that Ensilica currently has a market cap of around £60M. |
Posted at 08/3/2024 17:03 by john henry Placing shares will go into save hands. pretty much zero will be flipped.Investors will start focusing on recent contract wins once funding is secured. My guess is the BOD will participate quite heavily into the funding@ 10p |
Posted at 27/2/2024 07:44 by jnbrw The main guy here knows what he is doing. I would not be surprised in the least if there is no equity fundraise and just short term overdraft. Company is winning contracts all over the place and the Elon Musk/ Tesla/ Neuralink news is bringing the company and its quality products to the attention of new investors . |
Posted at 09/2/2024 08:56 by slicethepie Poor advice has got them into this situation. They are surrounded by advisers who only want fees and have no interest in the company. Unfortunately very few institutions invest in companies this small and the advisors don't know how to target hnw investors who are probably the source of capital for them |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
